345 related articles for article (PubMed ID: 22361632)
1. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort.
Cuzick J; Berney DM; Fisher G; Mesher D; Møller H; Reid JE; Perry M; Park J; Younus A; Gutin A; Foster CS; Scardino P; Lanchbury JS; Stone S;
Br J Cancer; 2012 Mar; 106(6):1095-9. PubMed ID: 22361632
[TBL] [Abstract][Full Text] [Related]
2. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort.
Cuzick J; Stone S; Fisher G; Yang ZH; North BV; Berney DM; Beltran L; Greenberg D; Møller H; Reid JE; Gutin A; Lanchbury JS; Brawer M; Scardino P
Br J Cancer; 2015 Jul; 113(3):382-9. PubMed ID: 26103570
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.
Cuzick J; Swanson GP; Fisher G; Brothman AR; Berney DM; Reid JE; Mesher D; Speights VO; Stankiewicz E; Foster CS; Møller H; Scardino P; Warren JD; Park J; Younus A; Flake DD; Wagner S; Gutin A; Lanchbury JS; Stone S;
Lancet Oncol; 2011 Mar; 12(3):245-55. PubMed ID: 21310658
[TBL] [Abstract][Full Text] [Related]
4. Measurements of cancer extent in a conservatively treated prostate cancer biopsy cohort.
Rajab R; Fisher G; Kattan MW; Foster CS; Oliver T; Møller H; Reuter V; Scardino P; Cuzick J; Berney DM;
Virchows Arch; 2010 Nov; 457(5):547-53. PubMed ID: 20827488
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.
Cuzick J; Yang ZH; Fisher G; Tikishvili E; Stone S; Lanchbury JS; Camacho N; Merson S; Brewer D; Cooper CS; Clark J; Berney DM; Møller H; Scardino P; Sangale Z;
Br J Cancer; 2013 Jun; 108(12):2582-9. PubMed ID: 23695019
[TBL] [Abstract][Full Text] [Related]
6. Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance.
Tosoian JJ; Chappidi MR; Bishoff JT; Freedland SJ; Reid J; Brawer M; Stone S; Schlomm T; Ross AE
BJU Int; 2017 Dec; 120(6):808-814. PubMed ID: 28481440
[TBL] [Abstract][Full Text] [Related]
7. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy.
Freedland SJ; Gerber L; Reid J; Welbourn W; Tikishvili E; Park J; Younus A; Gutin A; Sangale Z; Lanchbury JS; Salama JK; Stone S
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):848-53. PubMed ID: 23755923
[TBL] [Abstract][Full Text] [Related]
8. An improved prognostic model for stage T1a and T1b prostate cancer by assessments of cancer extent.
Rajab R; Fisher G; Kattan MW; Foster CS; Møller H; Oliver T; Reuter V; Scardino PT; Cuzick J; Berney DM;
Mod Pathol; 2011 Jan; 24(1):58-63. PubMed ID: 20834240
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of a cell-cycle progression score in men with prostate cancer managed with active surveillance after MRI-guided prostate biopsy--a pilot study.
Arsov C; Jankowiak F; Hiester A; Rabenalt R; Quentin M; Schimmöller L; Blondin D; Antoch G; Albers P
Anticancer Res; 2014 May; 34(5):2459-66. PubMed ID: 24778061
[TBL] [Abstract][Full Text] [Related]
10. Prediction of extraprostatic extension of prostate cancer based on needle biopsy findings: perineural invasion lacks significance on multivariate analysis.
Egan AJ; Bostwick DG
Am J Surg Pathol; 1997 Dec; 21(12):1496-500. PubMed ID: 9414194
[TBL] [Abstract][Full Text] [Related]
11. Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy.
Cuzick JM; Stone S; Lenz L; Flake DD; Rajamani S; Moller H; Berney DM; Cohen T; Scardino PT
Cancer Rep (Hoboken); 2022 Aug; 5(8):e1535. PubMed ID: 34423592
[TBL] [Abstract][Full Text] [Related]
12. Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer.
D'Amico AV; Wu Y; Chen MH; Nash M; Renshaw AA; Richie JP
J Urol; 2001 Jan; 165(1):126-9. PubMed ID: 11125380
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome among men with conservatively treated localised prostate cancer.
Cuzick J; Fisher G; Kattan MW; Berney D; Oliver T; Foster CS; Møller H; Reuter V; Fearn P; Eastham J; Scardino P;
Br J Cancer; 2006 Nov; 95(9):1186-94. PubMed ID: 17077805
[TBL] [Abstract][Full Text] [Related]
14. Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions.
Nelson CP; Dunn RL; Wei JT; Rubin MA; Montie JE; Sanda MG
Urol Oncol; 2003; 21(3):213-8. PubMed ID: 12810209
[TBL] [Abstract][Full Text] [Related]
15. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.
Cooperberg MR; Simko JP; Cowan JE; Reid JE; Djalilvand A; Bhatnagar S; Gutin A; Lanchbury JS; Swanson GP; Stone S; Carroll PR
J Clin Oncol; 2013 Apr; 31(11):1428-34. PubMed ID: 23460710
[TBL] [Abstract][Full Text] [Related]
16. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort.
Fisher G; Yang ZH; Kudahetti S; Møller H; Scardino P; Cuzick J; Berney DM;
Br J Cancer; 2013 Feb; 108(2):271-7. PubMed ID: 23329234
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy.
Canter DJ; Freedland S; Rajamani S; Latsis M; Variano M; Halat S; Tward J; Cohen T; Stone S; Schlomm T; Bishoff J; Bardot S
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):102-107. PubMed ID: 31243337
[TBL] [Abstract][Full Text] [Related]
19. Gleason score as predictor of clinicopathologic findings and biochemical (PSA) progression following radical prostatectomy.
Guimaraes MS; Quintal MM; Meirelles LR; Magna LA; Ferreira U; Billis A
Int Braz J Urol; 2008; 34(1):23-9. PubMed ID: 18341718
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen cancer volume: a significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy.
Lankford SP; Pollack A; Zagars GK
Int J Radiat Oncol Biol Phys; 1997 May; 38(2):327-33. PubMed ID: 9226319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
